JAVIER
PUENTE VÁZQUEZ
Profesor asociado de Ciencias de la Salud
B.
Pérez Valderrama
Publicaciones en las que colabora con B. Pérez Valderrama (9)
2022
-
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
European Journal of Cancer, Vol. 175, pp. 110-119
-
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
The Lancet Oncology, Vol. 23, Núm. 3, pp. 362-373
2020
-
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies
Annals of Oncology, Vol. 31, Núm. 9, pp. 1186-1197
2019
-
Prorepair-B: A prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer
Journal of Clinical Oncology, Vol. 37, Núm. 6, pp. 490-503
-
The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)
Targeted Oncology, Vol. 14, Núm. 1, pp. 15-32
2017
-
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial
The Lancet Oncology, Vol. 18, Núm. 5, pp. 672-681
-
Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma
Oncotarget, Vol. 8, Núm. 18, pp. 30410-30421
-
Recent advances in genitourinary tumors: A review focused on biology and systemic treatment
Critical Reviews in Oncology/Hematology, Vol. 113, pp. 171-190